Urology Times
@urologytimes.bsky.social
The Leading News Source for Urologists - http://UrologyTimes.com Expert clinical analysis. Practice advice. Policy perspectives.
WATCH 🎥: Veda Giri, MD, discusses national and international guideline recommendations for germline testing in prostate cancer. www.urologytimes.com/view/veda-gi...
Veda Giri, MD, on guidelines for germline testing in prostate cancer
Veda Giri, MD, outlines points of consensus and areas of disagreement across national and international guideline recommendations for germline testing in prostate cancer.
urologytimes.com
The FDA has granted breakthrough device designation to the Virtuoso Surgical Robotic System for bladder lesion removal via en bloc excision. www.urologytimes.com/view/fda-gra...
FDA grants breakthrough device designation to Virtuoso Surgical Robotic System
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
urologytimes.com
WATCH 🎥: Veeru Kasivisvanathan, MBBS, BSc, FRCS, MSc, PGCert, PhD, discusses findings from the PRIME trial, a multicenter, international study on the diagnostic performance of bpMRI vs mpMRI in prostate cancer detection. www.urologytimes.com/view/prime-t...
PRIME trial: bpMRI is found noninferior to mpMRI in prostate cancer
Ensuring consistent diagnostic quality remains critical.
urologytimes.com
BREAKING🚨: The FDA has approved pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection across previously approved solid tumor indications of intravenous pembrolizumab. www.urologytimes.com/view/fda-app...
FDA approves pembrolizumab for subcutaneous injection for solid tumors
The approval is supported by data from the phase 3 MK-3475A-D77 trial.
urologytimes.com
In this episode of First Assist: GU Oncology Unpacked, host Taylor Goodstein, MD, speaks with Kamal Pohar, MD, about the evolution of management and surveillance for NMIBC. www.urologytimes.com/view/first-a...
First Assist: The Historical Context of NMIBC, with Kamal Pohar, MD
Among the topics covered are BCG dosing and maintenance regimens.
urologytimes.com
BREAKING🚨: The #FDA has approved Medtronic's Altaviva device, an implantable tibial neuromoulation therapy for patients with urge urinary incontinence. www.urologytimes.com/view/fda-app...
FDA approves Altaviva device for urge urinary incontinence
The Altaviva device is a minimally invasive implantable tibial neuromodulation therapy for patients with urge urinary incontinence.
urologytimes.com
Additional results from the RAPID I study suggest that the FloStent device could serve as an effective interim solution for men with urinary retention due to BPH who are awaiting TURP. www.urologytimes.com/view/flosten...
FloStent device shows efficacy for acute urinary retention due to BPH
According to the authors, these findings suggest that FloStent could serve as an effective interim solution for men who are awaiting TURP.
urologytimes.com
Carotuximab in combination with apalutamide achieved encouraging progression-free survival in patients with mCRPC. www.urologytimes.com/view/carotux...
Carotuximab plus apalutamide demonstrates promising PFS in mCRPC
The phase 2 trial has shown encouraging safety and efficacy results for carotuximab and apalutamide in patients with mCRPC.
urologytimes.com
The Dornier Hoover Flexible and Navigable Suction Ureteral Access Sheath and Dornier Axis II Slim single-use ureteroscope are now commercially available in the US. www.urologytimes.com/view/dornier...
Dornier single-use ureteroscope and ureteral access sheath launch on US market
Both the Dornier Hoover Flexible and Navigable Suction Ureteral Access Sheath and the Dornier Axis II Slim single-use ureteroscope are FDA-cleared.
urologytimes.com
WATCH 🎥: Jane T. Kurtzman, MD, discusses findings from her study on the long-term risk of hypertension following renal trauma. www.urologytimes.com/view/data-po...
Data point to value of hypertension counseling following renal trauma
Jane T. Kurtzman, MD, underscores the collaborative role of urologists and trauma surgeons in addressing this issue.
urologytimes.com
WATCH 🎥: John P. Sfakianos, MD, discusses the use of urine-based tumor markers to guide decision-making in hematuria evaluation. www.urologytimes.com/view/john-p-...
John P. Sfakianos, MD, on the role of urine-based biomarkers in microhematuria evaluation
John P. Sfakianos, MD, discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA study.
urologytimes.com
WATCH 🎥: A. Lenore Ackerman, MD, PhD, discusses the renewed emphasis on symptom resolution over microbial eradication for treatment success in the updated AUA guideline for recurrent uUTI in women. www.urologytimes.com/view/recurre...
Recurrent uUTI guideline: Renewed emphasis on symptom resolution
A. Lenore Ackerman, MD, PhD, discusses the renewed emphasis on symptom resolution over microbial eradication in the new AUA guideline for recurrent uUTI in women.
urologytimes.com
Biparametric MRI was found to be noninferior to multiparametric MRI in the detection of clinically significant prostate cancer, according to recent findings from the PRIME trial. www.urologytimes.com/view/biparam...
Biparametric MRI is noninferior to multiparametric MRI for prostate cancer diagnosis
According to the authors, these findings suggest that biparametric MRI could become the new standard of care for prostate cancer diagnosis.
urologytimes.com
Andrew J. Kirsch, MD, FAAP, FACS, outlines current gaps and opportunities in enuresis treatment. www.urologytimes.com/view/a-pedia...
A pediatric urologist outlines gaps and opportunities in enuresis treatment
Andrew J. Kirsch, MD, FAAP, FACS, outlines current therapies, ranging from behavioral strategies, such as limiting fluids before bedtime, to bedwetting alarms and medications like DDAVP.
urologytimes.com
WATCH 🎥: Stephen J. Freedland, MD, highlights the role of diet in prostate cancer management. www.urologytimes.com/view/stephen...
Stephen J. Freedland, MD, highlights the role of diet in prostate cancer management
Among men without prostate cancer at baseline, healthier dietary patterns appeared somewhat protective.
urologytimes.com
In a recent interview with Urology Times, Sia Daneshmand, MD, shared his thoughts on the recent #FDA approval of the gemcitabine intravesical system (Inlexzo; formerly TAR-200) for BCG-unresponsive NMIBC. Find his insights here: www.urologytimes.com/view/behind-...
Andrea B. Apolo, MD, discusses immune checkpoint inhibition as adjuvant and perioperative therapy in MIBC. www.urologytimes.com/view/andrea-...
Andrea B. Apolo, MD, discusses ICI therapy in MIBC
Apolo emphasized the value of having robust monotherapy data before advancing into combination strategies.
urologytimes.com
New 2-year outcomes from the ASPIRE trial were presented at #WCET25, showing that patients who underwent the SURE procedure had a lower risk of health care consumption events than those who underwent URS. www.urologytimes.com/view/sure-pr...
SURE procedure linked with lower healthcare utilization vs URS
Two-year outcomes from the ASPIRE trial continued to show that the SURE procedure led to significantly reduced health care consumption events compared with ureteroscopy.
urologytimes.com
Japan’s Pharmaceuticals and Medical Devices Agency has accepted for review a new drug application for nadofaragene firadenovec in high-risk BCG-unresponsive NMIBC. www.urologytimes.com/view/nadofar...
Nadofaragene firadenovec under regulatory review in Japan
The NDA is supported by data from a phase 3 trial, which demonstrated a 75% complete response rate at 3 months.
urologytimes.com
Data from a phase 1b study showed encouraging preliminary symptom improvement with sunobinop in patients with interstitial cystitis/bladder pain syndrome. www.urologytimes.com/view/sunobin...
Sunobinop shows promising efficacy in interstitial cystitis/bladder pain syndrome
Data showed a marked or moderate improvement in IC/BPS symptoms in 41% of patients who received sunobinop vs 9% of patients who received placebo.
urologytimes.com
BREAKING🚨: The FDA has approved gemcitabine intravesical system (Inlexzo; formerly TAR-200) for adult patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors. www.urologytimes.com/view/fda-app...
FDA approves gemcitabine intravesical system for BCG-unresponsive high-risk NMIBC
Data from the SunRISe-1 trial showed a complete response rate of 82%, with 51% of patients remaining in complete response for at least 1 year.
urologytimes.com
WATCH 🎥: Henry C. Wright IV, MD, and Jennifer Miles-Thomas, MD, URPS, MBA, highlighted Northwestern Medicine Urology’s successful integration of AI technology into clinical practice. www.urologytimes.com/view/physici...
Physician-led implementation drives AI success in urology
Miles-Thomas emphasized the importance of Northwestern’s thoughtful implementation strategy.
urologytimes.com
Jonathan Rubenstein, MD, and Mark Painter summarize key provisions outlined in the Medicare proposed rule for 2026. www.urologytimes.com/view/medicar...
Medicare proposed rule for 2026: CMS, what are you doing to us?
"Based on this proposal, some shifts may significantly impact the practice of urology," write Jonathan Rubenstein, MD, and Mark Painter.
urologytimes.com
Rana McKay, MD, FASCO, outlines key takeaways from the COMRADE trial of olaparib plus radium-223 in CRPC. www.urologytimes.com/view/key-tak...
Key takeaways from the COMRADE trial in CRPC, with Rana McKay, MD
Rana R. McKay, MD, FASCO, highlights notable takeaways from the COMRADE trial, assessing the combination of olaparib plus radium-223 in CRPC.
urologytimes.com
Kevin Koo, MD, MPH, recently sat down with Urology Times to discuss a study on the impact of a digital stone measurement tool on surgeon decision-making during ureteroscopy. www.urologytimes.com/view/kevin-k...
Kevin Koo, MD, MPH, on a digital stone measurement tool for ureteroscopy
Kevin Koo, MD, MPH, discusses a recent study on the utility of a digital stone measurement tool for ureteroscopy.
urologytimes.com
WATCH 🎥: Stephen J. Freedland, MD, discusses findings from a recent systematic review examining the relationship between diet and prostate cancer risk and outcomes. www.urologytimes.com/view/systema...
Systematic review highlights diet’s role in prostate cancer outcomes
Surprisingly, the Mediterranean diet—which has shown benefits in other areas of health—was not consistently linked to prostate cancer risk reduction.
urologytimes.com
Updated data from cohort C of the BOND-003 trial show consistent efficacy and favorable tolerability with cretostimogene grenadenorepvec in patients with high-risk BCG-unresponsive NMIBC. Learn more: www.urologytimes.com/view/updated...
Updated BOND-003 data support durability of cretostimogene grenadenorepvec in NMIBC
CG Oncology plans to initiate a BLA submission with the FDA in Q4 of 2025.
urologytimes.com
Investigators at Johns Hopkins Medicine and collaborating institutions have developed a noninvasive urine test that shows strong promise in detecting prostate cancer. www.urologytimes.com/view/urine-b...
Urine biomarker assay outperforms PCA3 in prostate cancer diagnosis
The biomarker panel demonstrated the ability to detect prostate cancer even in men with prostate-specific antigen levels in the normal range.
urologytimes.com
The pivotal cohort in the phase 2 LEGEND trial, exploring detalimogene voraplasmid in high-risk NMIBC, has reached its enrollment goal. www.urologytimes.com/view/pivotal...
Pivotal cohort in LEGEND trial reaches target enrollment
The LEGEND trial is evaluating detalimogene voraplasmid in patients with high-risk non–muscle invasive bladder cancer.
urologytimes.com
The enrollment goal has been met in the phase 3 PIVOT-006 trial, which is comparing RFS with cretostimogene grenadenorepvec vs surveillance following TURBT in patients with IR-NMIBC. www.urologytimes.com/view/enrollm...
Enrollment goal met in PIVOT-006 trial of cretostimogene grenadenorepvec in IR-NMIBC
The trial is assessing RFS rates with cretostimogene grenadenorepvec vs surveillance following TURBT.
urologytimes.com